http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo#Head
http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo#assertion
http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo#provenance
http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo#pubinfo
http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo#assertion
http://purl.obolibrary.org/obo/DOID_9538
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_9538
http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB06603
http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo#association
http://www.w3.org/2000/01/rdf-schema#label
farydak a histone deacetylase inhibitor in combination with bortezomib and dexamethasone is indicated for the treatment of patients with multiple myeloma who have received at least 2 prior regimens including bortezomib and an immunomodulatory agent this indication is approved under accelerated approval based on progression free survival see clinical studies 14 1 farydak a histone deacetylase inhibitor in combination with bortezomib and dexamethasone is indicated for the treatment of patients with multiple myeloma who have received at least 2 prior regimens including bortezomib and an immunomodulatory agent this indication is approved under accelerated approval based on progression free survival continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials 1
http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB06603
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo#provenance
http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo#pubinfo
http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo#sig
http://purl.org/nanopub/x/hasSignature
ejkgAdelRbCwcop+mYWEroyL/NoOAY7gyM1L+ZFCVYs6Rwd0q3O9FNXnkpo3VVcRMm27MPR1G6sunrxvFiJiW+Uf8lA/2E69+oJ5H/TwEFQig80kKP4b0asdnp+L7gJIeO7UZwJLfhJjLHonTahakeB63rj8bPjvaEonSWoXJpM=
http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo
http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo
http://purl.org/dc/terms/created
2021-06-12T13:26:08.716+02:00
http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs